Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
Taro Edahiro,
Hiroshi Ureshino,
Ren Chishaki,
Keita Fujino,
Tatsuji Mino,
Tetsumi Yoshida,
Noriyasu Fukushima,
Tatsuo Ichinohe
Affiliations
Taro Edahiro
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Hiroshi Ureshino
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Ren Chishaki
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Keita Fujino
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Tatsuji Mino
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Tetsumi Yoshida
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Noriyasu Fukushima
Department of Internal Medicine Karatsu Red Cross Hospital Karatsu Japan
Tatsuo Ichinohe
Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine Hiroshima University Hiroshima Japan
Abstract Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The case of a patient with 11q23/MLL‐rearranged AML who successfully underwent a third allogeneic stem cell transplantation after treatment with azacitidine (AZA) and venetoclax (VEN) is presented in this article. This report suggests that a combination of AZA and VEN is an effective therapeutic approach for relapsed and refractory MLL‐rearranged AML.
